First-in-human Study of SAR448632 in Healthy Adult Participants
A Randomized, First-in-human, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of SAR448632 in Healthy Adult Participants
This is a randomized, first-in-human, placebo-controlled, double-blind, Phase 1 study to assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and target engagement after sequential single ascending doses of SAR448632 in healthy adult male and female participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Trial Transparency email recommended (Toll free for US & Canada)
- Phone Number: option 6 800-633-1610
- Email: Contact-US@sanofi.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- Body weight between 45.0 and 95.0 kg, inclusive; Body Mass Index (BMI) between 18.5 and 27.9 kg/m², inclusive.
- Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic, or infectious disease, or signs of acute illness.
- Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
- Any volume of blood donation, or blood loss >200 mL, within 2 months before inclusion.
- History or presence of drug or alcohol abuse.
- Regular smoking regularly more than 5 cigarettes or equivalent in nicotine per week, unable to stop smoking (occasional smoker can be enrolled).
- Symptomatic herpes zoster within 3 months prior to Screening.
- History of recurrent oral or genital herpes.
- Any history of active or latent Tuberculosis (TB).
- Participants with fever (temperature >38℃), active infection requiring systemic treatment at screening, chronic or recurrent infections requiring systemic treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to screening, or any history of chronic or recurrent infections suggesting underlying immune dysfunction, as deemed unacceptable by the Investigator.
- Any biologics (antibody or its derivatives) given within 4 months before inclusion.
- Vaccination: Receipt of live (attenuated) vaccines within 3 months and/or non-live vaccines within 4 weeks prior to randomization on Day 1, or planned to receive these vaccines at any time throughout the study.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SAR448632
Participants will receive a single dose of SAR448632 by SC injection or infusion on Day 1 only. |
Route of administration: SC injection or infusion |
|
Placebo Comparator: Placebo
The placebo administration will match the dosing planned for SAR448632 |
Administration method will match SAR448632 |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with assessment of Adverse Events (AEs) / Treatment-Emergent Adverse Events (TEAEs), including Injection Site Reactions (ISRs)
Time Frame: Baseline to day 113
|
Assessment of AEs/TEAEs including ISRs. |
Baseline to day 113
|
|
Number of participants with potentially clinically significant abnormalities in clinical laboratory evaluation; Vital signs; 12-lead Electrocardiogram.
Time Frame: Baseline to day 113
|
Clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis); Vital signs; 12-lead ECG (heart rate, PR, QRS, QT, QTcF). |
Baseline to day 113
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum observed plasma concentration (Cmax )
Time Frame: Baseline to day 99
|
Baseline to day 99
|
|
Time to reach maximum observed plasma concentration (tmax )
Time Frame: Baseline to day 99
|
Baseline to day 99
|
|
Area under the plasma concentration-time curve (AUC)
Time Frame: Baseline to day 99
|
Baseline to day 99
|
|
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC last ).
Time Frame: Baseline to day 99
|
Baseline to day 99
|
|
Incidence of participants with presence of Anti-Drug Antibody (ADA) against SAR448632.
Time Frame: Baseline to day 99
|
Baseline to day 99
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SAD21938
- U1111-1339-2949 (Registry Identifier: ICTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.